{"id":"medium-dose-anrikefon","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Dizziness"},{"rate":"5-10%","effect":"Headache"},{"rate":"5-10%","effect":"Nausea"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"By blocking the sodium channel, anrikefon reduces the abnormal electrical activity in the heart that can lead to arrhythmias. This results in a more stable heart rhythm and reduced risk of stroke. Anrikefon's mechanism of action is specific to the Nav1.5 channel, which is primarily responsible for the repolarization phase of the cardiac action potential.","oneSentence":"Anrikefon is a selective inhibitor of the sodium channel Nav1.5, which helps to regulate the heart's rhythm.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:54:22.083Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Atrial fibrillation for stroke prevention"}]},"trialDetails":[{"nctId":"NCT07246785","phase":"PHASE4","title":"Anrikefon-based Patient-controlled Intravenous Analgesia After Laparoscopic Surgery","status":"RECRUITING","sponsor":"Peking University First Hospital","startDate":"2025-12-25","conditions":"Laparoscopic Surgery, Visceral Pain, Postoperative, Anrikefon","enrollment":140}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Medium-dose anrikefon-based patient-controlled analgesia"],"phase":"marketed","status":"active","brandName":"Medium-dose anrikefon","genericName":"Medium-dose anrikefon","companyName":"Peking University First Hospital","companyId":"peking-university-first-hospital","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Anrikefon is a medication that has been studied in clinical trials for use in patient-controlled intravenous analgesia after laparoscopic surgery. The exact mechanism of anrikefon is unknown, according to ChEMBL.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}